Targeting Inflammation in Heart Failure with Histone Deacetylase Inhibitors
Targeting Inflammation in Heart Failure with Histone Deacetylase Inhibitors
复制标题
DOI：
10.2119/molmed.2011.00022
复制
发表时间：
2011-05-01
影响因子：
5.7
通讯作者：
McKinsey, Timothy A.
中科院分区：
文献类型：
--
作者：
McKinsey, Timothy A.
心肌梗死和慢性高血压等心血管损伤可触发心脏重塑过程，其特征是心肌细胞肥大、心肌细胞死亡和纤维化，通常导致心功能受损和心力衰竭。病理性心脏重构与炎症有关，针对炎症级联反应的治疗方法在心力衰竭患者中显示出良好的前景。小分子组蛋白脱乙酰酶(HDAC)抑制剂在动物模型中阻断了不利的心脏重构，表明这类化合物在治疗心力衰竭方面具有不可预见的潜力。除了它们对心肌细胞的有益作用外。HDAC抑制剂有很强的抗炎作用。该综述重点介绍了HDAC在心脏中的作用，以及将HDAC抑制剂作为基础广泛的免疫调节剂用于治疗人类心力衰竭的可能性。(C)2011年范斯坦医学研究所，网址：http://www.molmed.org doi：10.2119/molmed.2011.00022
Cardiovascular insults such as myocardial infarction and chronic hypertension can trigger the heart to undergo a remodeling process characterized by myocyte hypertrophy, myocyte death and fibrosis, often resulting in impaired cardiac function and heart failure. Pathological cardiac remodeling is associated with inflammation, and therapeutic approaches targeting inflammatory cascades have shown promise in patients with heart failure. Small molecule histone deacetylase (HDAC) inhibitors block adverse cardiac remodeling in animal models, suggesting unforeseen potential for this class of compounds for the treatment of heart failure. In addition to their beneficial effects on myocardial cells. HDAC inhibitors have potent antiinflammatory actions. This review highlights the roles of HDACs in the heart and the potential for using HDAC inhibitors as broad-based immunomodulators for the treatment of human heart failure. (C) 2011 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2011.00022